200 Ne Mother Joseph Pl Suite 110
Vancouver WA 98664
Medical School: University Of Rochester School Of Medicine And Dentistry - 1997
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: Yes
Participates In EHR: Yes
License #: MD43407
Request Appointment Information
Awards & Recognitions
Dr. Hoang Le is associated with these group practices
|HCPCS Code||Description||Average Price||Average Price
Allowed By Medicare
|HCPCS Code:63047||Description:Removal of spinal lamina||Average Price:$2,978.95||Average Price Allowed
|HCPCS Code:63048||Description:Remove spinal lamina add-on||Average Price:$574.64||Average Price Allowed
|HCPCS Code:99204||Description:Office/outpatient visit new||Average Price:$357.21||Average Price Allowed
|HCPCS Code:99214||Description:Office/outpatient visit est||Average Price:$231.65||Average Price Allowed
|HCPCS Code:99213||Description:Office/outpatient visit est||Average Price:$156.37||Average Price Allowed
|HCPCS Code:72110||Description:X-ray exam of lower spine||Average Price:$117.93||Average Price Allowed
|HCPCS Code:99212||Description:Office/outpatient visit est||Average Price:$94.44||Average Price Allowed
|HCPCS Code:72100||Description:X-ray exam of lower spine||Average Price:$89.63||Average Price Allowed
|HCPCS Code:72040||Description:X-ray exam of neck spine||Average Price:$87.51||Average Price Allowed
HCPCS Code Definitions
- Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; each additional segment, cervical, thoracic, or lumbar (List separately in addition to code for primary procedure)
- Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; lumbar
- Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
- Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
- Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
- Radiologic examination, spine, lumbosacral; minimum of 4 views
- Radiologic examination, spine, cervical; 2 or 3 views
- Radiologic examination, spine, lumbosacral; 2 or 3 views
- Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
Medical Malpractice Cases
Medical Board Sanctions
Cardiovascular Disease (Cardiology)
Physical Medicine And Rehabilitation
*These referrals represent the top 10 that Dr. Le has made to other doctors
Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase. - ACS medicinal chemistry letters
Hepatocellular carcinoma is the second leading cause of cancer death worldwide. DNA microarray analysis identified the ornithine aminotransferase (OAT) gene as a prominent gene overexpressed in hepatocellular carcinoma (HCC) from Psammomys obesus. In vitro studies demonstrated inactivation of OAT by gabaculine (1), a neurotoxic natural product, which suppressed in vitro proliferation of two HCC cell lines. Alpha-fetoprotein (AFP) secretion, a biomarker for HCC, was suppressed by gabaculine in both cell lines, but not significantly. Because of the active site similarity between GABA aminotransferase (GABA-AT) and OAT, a library of 24 GABA-AT inhibitors was screened to identify a more selective inhibitor of OAT. (1S,3S)-3-Amino-4-(hexafluoropropan-2-ylidene)cyclopentane-1-carboxylic acid (2) was found to be an inactivator of OAT that only weakly inhibits GABA-AT, l-aspartate aminotransferase, and l-alanine aminotransferase. In vitro administration of 2 significantly suppressed AFP secretion in both Hep3B and HepG2 HCC cells; in vivo, 2 significantly suppressed AFP serum levels and tumor growth in HCC-harboring mice, even at 0.1 mg/kg. Overexpression of the OAT gene in HCC and the ability to block the growth of HCC by OAT inhibitors support the role of OAT as a potential therapeutic target to inhibit HCC growth. This is the first demonstration of suppression of HCC by an OAT inactivator.
Coherent diffractive imaging microscope with a high-order harmonic source. - Applied optics
We report the generation of highly coherent extreme ultraviolet sources with wavelengths around 30 and 10 nm by phase-matched high-order harmonic generation (HHG) in a gas cell filled with argon and helium, respectively. We then perform coherent diffractive imaging (CDI) by using a focused narrow-bandwidth HHG source with wavelength around 30 nm as an illumination beam for two kinds of samples. The first is a transmission sample and the second is a absorption sample. In addition, we report the successful reconstruction of a complex absorption sample using a tabletop high-harmonic source. This will open the path to the realization of a compact soft x-ray microscope to investigate biological samples such as membrane proteins.
Visual Acuity in Birdshot Retinochoroidopathy Evaluation. - American journal of ophthalmology
To determine the statistical correlation between visual acuity (VA) and various quantitative parameters relevant to birdshot retinochoroidopathy (BRC) evaluation.Hospital-based retrospective observational study.setting: Institutional.Consecutive HLA29+ BRC patients were included between May and August 2013 at a single tertiary center (PitiÃ©-SalpÃ©triÃ¨re Hospital, Paris).Demographic data and quantitative parameters relevant to BRC at baseline were collected: VA, degree of anterior and posterior inflammatory reaction, foveal thickness measured by optical coherence tomography (OCT), Arden ratio, and electrooculography (EOG) light peak.Correlation between VA and the other parameters of the ipsilateral and fellow eye was performed using Spearman rank correlation coefficients.Fifty-five patients were included. Mean VA was 6/9.5 in the right eye (OD) and 6/12 in the left eye (OS). Mean foveal thickness was 240Â Î¼m OD (range: 112-606) and 251Â Î¼m OS (range: 85-662). Mean Arden ratio was 159% OD and 160% OS. EOG light peak was 714Â mV OD (range: 316-1379) and 746Â mV OS (range: 272-1652). VA of a given eye was moderately correlated with VA of the contralateral eye (rÂ = 0.4). On the contrary, all other parameters showed a strong correlation between both eyes (all r > 0.7, P < .01). Overall, none of the studied parameters was correlated with its VA (all r < 0.5).In BRC, visual acuity alone does not seem to fully reflect the disease severity in terms of clinical or ancillary quantitative findings at baseline.Copyright Â© 2015 Elsevier Inc. All rights reserved.
Efficacy of anti-TNF alpha in severe and/or refractory BehÃ§et's disease: Multicenter study of 124 patients. - Journal of autoimmunity
To report the efficacy and safety of anti-TNF agents in patients with severe and/or refractory manifestations of BehÃ§et's disease (BD).We performed a multicenter study of main characteristics and outcomes of anti-TNF alpha treatments [mainly infliximab (62%), and adalimumab (30%)] in 124 BD patients [48% of men; median age of 33.5 (28-40) years].Overall response (i.e. complete and partial) rate was 90.4%. Clinical responses were observed in 96.3%, 88%, 70%, 77.8%, 92.3% and 66.7% of patients with severe and/or refractory ocular, mucocutaneous, joint, gastro-intestinal manifestations, central nervous system manifestations and cardiovascular manifestations, respectively. No significant difference was found with respect to the efficacy of anti-TNF used as monotherapy or in association with an immunosuppressive agent. The incidence of BD flares/patient/year was significantly lower during anti-TNF treatment (0.2Â Â±Â 0.5 vs 1.7Â Â±Â 2.4 before the use of anti-TNF, pÂ <Â 0.0001). The prednisone dose was significantly reduced at 6 and 12 months (pÂ <Â 0.0001). In multivariate analysis, retinal vasculitis was negatively associated with complete response to anti-TNF (ORÂ =Â 0.33 [0.12-0.89]; pÂ =Â 0.03). The efficacy and relapse free survival were similar regardless of the type of anti-TNF agent used. After a median follow-up of 21 [7-36] months, side effects were reported in 28% of patients, including infections (16.3%) and hypersensitivity reactions (4.1%). Serious adverse events were reported in 13% of cases.Anti-TNF alpha therapy is efficient in all severe and refractory BD manifestations. Efficacy appears to be similar regardless of the anti-TNF agent used (infliximab or adalimumab).Copyright Â© 2015 Elsevier Ltd. All rights reserved.
Hybrid Molecule-Nanocrystal Photon Upconversion Across the Visible and Near-Infrared. - Nano letters
The ability to upconvert two low energy photons into one high energy photon has potential applications in solar energy, biological imaging, and data storage. In this Letter, CdSe and PbSe semiconductor nanocrystals are combined with molecular emitters (diphenylanthracene and rubrene) to upconvert photons in both the visible and the near-infrared spectral regions. Absorption of low energy photons by the nanocrystals is followed by energy transfer to the molecular triplet states, which then undergo triplet-triplet annihilation to create high energy singlet states that emit upconverted light. By using conjugated organic ligands on the CdSe nanocrystals to form an energy cascade, the upconversion process could be enhanced by up to 3 orders of magnitude. The use of different combinations of nanocrystals and emitters shows that this platform has great flexibility in the choice of both excitation and emission wavelengths.
Mechanism of Inactivation of GABA Aminotransferase by (E)- and (Z)-(1S,3S)-3-Amino-4-fluoromethylenyl-1-cyclopentanoic Acid. - ACS chemical biology
When Î³-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the mammalian central nervous system, falls below a threshold level, seizures occur. One approach to raise GABA concentrations is to inhibit GABA aminotransferase (GABA-AT), a pyridoxal 5'-phosphate-dependent enzyme that degrades GABA. We have previously developed (1S,3S)-3-amino-4-difluoromethylene-1-cyclopentanoic acid (CPP-115), which is 186 times more efficient in inactivating GABA-AT than vigabatrin, the only FDA-approved inactivator of GABA-AT. We also developed (E)- and (Z)-(1S,3S)-3-amino-4-fluoromethylenyl-1-cyclopentanoic acid (1 and 2, respectively), monofluorinated analogs of CPP-115, which are comparable to vigabatrin in inactivating GABA-AT. Here, we report the mechanism of inactivation of GABA-AT by 1 and 2. Both produce a metabolite that induces disruption of the Glu270-Arg445 salt bridge to accommodate interaction between the metabolite formyl group and Arg445. This is the second time that Arg445 has interacted with a ligand and is involved in GABA-AT inactivation, thereby confirming the importance of Arg445 in future inactivator design.
Anti-inflammatory Activity of Pyrrolizidine Alkaloids from the Leaves of Madhuca pasquieri (Dubard). - Chemical & pharmaceutical bulletin
A novel pyrrolizidine alkaloids, madhumidine A (1), and two known alkaloids, lindelofidine benzoic acid ester (2) and minalobine B (3) were isolated from the leaves of Madhuca pasquieri (Dubard) H. J. LAM. The chemical structures of these alkaloids were established mainly by NMR techniques and mass spectrometry. Their anti-inflammatory activity was evaluated against lipopolysaccharide-induced nitric oxide production in macrophage RAW264.7 cell. In addition, the cytotoxic activity of all isolated compounds was tested against a panel of cancer cell lines.
Application of ultrasound to microencapsulation of coconut milk fat by spray drying method. - Journal of food science and technology
Mixtures of coconut milk and gelatin solution were treated by ultrasound, mixed with maltodextrin and subsequently spray-dried to yield powder. The effects of ultrasonic power and sonication time on the microencapsulation efficiency (ME) and microencapsulation yield (MY) of coconut fat were investigated. The results indicated that increase in ultrasonic power from 0 to 5.68Â W/g and in sonication time from 0 to 2.5Â min augmented ME and MY of coconut fat. However, treatment with sonication power higher than 5.68Â W/g led to a drop in fat ME and MY, mainly due to aggregation of fat particles and that blocked the adsorption of gelatin molecules on the particle surface.
Design and mechanism of tetrahydrothiophene-based Î³-aminobutyric acid aminotransferase inactivators. - Journal of the American Chemical Society
Low levels of Î³-aminobutyric acid (GABA), one of two major neurotransmitters that regulate brain neuronal activity, are associated with many neurological disorders, such as epilepsy, Parkinson's disease, Alzheimer's disease, Huntington's disease, and cocaine addiction. One of the main methods to raise the GABA level in human brain is to use small molecules that cross the blood-brain barrier and inhibit the activity of Î³-aminobutyric acid aminotransferase (GABA-AT), the enzyme that degrades GABA. We have designed a series of conformationally restricted tetrahydrothiophene-based GABA analogues with a properly positioned leaving group that could facilitate a ring-opening mechanism, leading to inactivation of GABA-AT. One compound in the series is 8 times more efficient an inactivator of GABA-AT than vigabatrin, the only FDA-approved inactivator of GABA-AT. Our mechanistic studies show that the compound inactivates GABA-AT by a new mechanism. The metabolite resulting from inactivation does not covalently bind to amino acid residues of GABA-AT but stays in the active site via H-bonding interactions with Arg-192, a Ï€-Ï€ interaction with Phe-189, and a weak nonbonded SÂ·Â·Â·Oâ•C interaction with Glu-270, thereby inactivating the enzyme.
Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. - JAMA ophthalmology
The best treatment option for primary vitreoretinal lymphoma (PVRL) without signs of central nervous system lymphoma (CNSL) involvement determined on magnetic resonance imaging or in cerebrospinal fluid is unknown.To evaluate the outcomes of treatment regimens used for PVRL in the prevention of subsequent CNSL.A retrospective cohort study was conducted at 17 referral ophthalmologic centers in Europe. We reviewed clinical, laboratory, and imaging data on 78 patients with PVRL who did not have CNSL on presentation between January 1, 1991, and December 31, 2012, with a focus on the incidence of CNS manifestations during the follow-up period.The term extensive treatment was used for various combinations of systemic and intrathecal chemotherapy, whole-brain radiotherapy, and peripheral blood stem cell transplantation. Therapy to prevent CNSL included ocular radiotherapy and/or ocular chemotherapy (group A, 31 patients), extensive systemic treatment (group B,â€‰21 patients), and a combination of ocular and extensive treatment (group C,â€‰23 patients); 3 patients did not receive treatment. A total of 40 patients received systemic chemotherapy.Development of CNSL following the diagnosis of PVRL relative to the use or nonuse of systemic chemotherapy and other treatment regimens.Overall, CNSL developed in 28 of 78 patients (36%) at a median follow-up of 49 months. Specifically, CNSL developed in 10 of 31 (32%) in group A, 9 of 21 (43%) in group B, and 9 of 23 (39%) in group C. The 5-year cumulative survival rate was lower in patients with CNSL (35% [95% CI, 50% to 86%]) than in patients without CNSL (68% [95% CI, 19% to 51%]; Pâ€‰=â€‰.003) and was similar among all treatment groups (Pâ€‰=â€‰.10). Adverse systemic effects occurred in 9 of 40 (23%) patients receiving systemic chemotherapy; the most common of these effects was acute renal failure.In the present series of patients with isolated PVRL, the use of systemic chemotherapy was not proven to prevent CNSL and was associated with more severe adverse effects compared with local treatment.
Map & Directions
200 Ne Mother Joseph Pl Suite 110 Vancouver, WA 98664
505 Ne 87Th Ave Suite 120
200 Ne Mother Joseph Pl Suite 110